View source for Chemistry:Pacritinib

{{Short description|Medication used to treat myelofibrosis}}
{{Infobox drug
| type              = <!-- empty -->
| image = Pacritinib skeletal.svg
| width = 230
| alt = 
| caption =

<!-- Clinical data -->
| pronounce         = 
| tradename = Vonjo 
| Drugs.com = 
| MedlinePlus = 
| DailyMedID        = Pacritinib
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment = 
| pregnancy_category= 
| routes_of_administration = [[Medicine:Oral administration|By mouth]]
| class             = 
| ATC_prefix = L01
| ATC_suffix = EJ03
| ATC_supplemental  = 

<!-- Legal status -->
| legal_AU          = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_AU_comment  = 
| legal_BR          = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F -->
| legal_BR_comment  = 
| legal_CA          = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment  = 
| legal_DE          = <!-- Anlage I, II, III or Unscheduled -->
| legal_DE_comment  = 
| legal_NZ          = <!-- Class A, B, C -->
| legal_NZ_comment  = 
| legal_UK          = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment  = 
| legal_US          = Rx-only
| legal_US_comment  = <ref name="Vonjo FDA label">{{cite web | title=Vonjo- pacritinib capsule | website=DailyMed | date=7 March 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5ab444-0e1a-4984-99db-76ad11a298ee | access-date=24 March 2022}}</ref><ref name="FDA 20220301" />
| legal_EU          = 
| legal_EU_comment  = 
| legal_UN          = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment  = 
| legal_status      = <!-- For countries not listed above -->

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| metabolites       = 
| onset             = 
| elimination_half-life = 
| duration_of_action = 
| excretion         = 

<!-- Identifiers -->
| CAS_number = 937272-79-2
| CAS_supplemental  = 
| PubChem = 46216796
| IUPHAR_ligand     = 
| DrugBank = DB11697
| ChemSpiderID = 28518965 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = G22N65IL3O
| KEGG = D11768
| ChEBI             = 
| ChEMBL = 2035187
| NIAID_ChemDB      = 
| PDB_ligand        = 6T3
| synonyms = SB1518

<!-- Chemical and physical data -->
| IUPAC_name = (16''E'')-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,26-triazatetracyclo[19.3.1.1<sup>2,6</sup>.1<sup>8,12</sup>]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
| C=28 | H=32 | N=4 | O=3
| SMILES = c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5
| StdInChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
| StdInChI_comment  = 
| StdInChIKey = HWXVIOGONBBTBY-ONEGZZNKSA-N
| density           = 
| density_notes     = 
| melting_point     = 
| melting_high      = 
| melting_notes     = 
| boiling_point     = 
| boiling_notes     = 
| solubility        = 
| sol_units         = 
| specific_rotation = 
}}

'''Pacritinib''', sold under the brand name '''Vonjo''', is an anti-cancer medication used to treat [[Medicine:Myelofibrosis|myelofibrosis]].<ref name="Vonjo FDA label" /><ref name="FDA 20220301" /> It is a macrocyclic [[Chemistry:Protein kinase inhibitor|protein kinase inhibitor]]. It mainly inhibits [[Biology:Janus kinase 2|Janus kinase 2]] (JAK2) and [[Biology:CD135|Fms-like tyrosine kinase 3\CD135]] (FLT3).

Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs.<ref name="FDA 20220301" />

== Medical uses ==
Pacritinib in indicated to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis and who have platelet (blood clotting cells) levels below 50,000/µL.<ref name="Vonjo FDA label" /><ref name="FDA 20220301">{{cite web | title=FDA approves drug for adults with rare form of bone marrow disorder | website=U.S. Food and Drug Administration | date=1 March 2022 | url=https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-adults-rare-form-bone-marrow-disorder | access-date=3 March 2022}} {{PD-notice}}</ref>

== History ==
The effectiveness and safety of pacritinib were demonstrated in a study that included 63 participants with intermediate or high-risk primary or secondary myelofibrosis and low platelets who received pacritinib 200{{nbsp}}mg twice daily or standard treatment.<ref name="FDA 20220301" /> Effectiveness was determined based upon the proportion of participants who had a 35% or greater spleen volume reduction from baseline to week 24.<ref name="FDA 20220301" /> Nine participants (29%) in the pacritinib treatment group had a 35% or greater spleen volume reduction, compared to one participant (3%) in the standard treatment group.<ref name="FDA 20220301" />

The U.S. [[Organization:Food and Drug Administration|Food and Drug Administration]] (FDA) granted the application for pacritinib [[Medicine:Priority review|priority review]], fast track, and [[Chemistry:Orphan drug|orphan drug]] designations.<ref name="FDA 20220301" />

== Society and culture ==
=== Names ===
Pacritinib is the [[Medicine:International nonproprietary name|International nonproprietary name]] (INN).<ref>{{cite journal | vauthors = ((World Health Organization)) | title = International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 104 | journal = WHO Drug Information | volume = 24 | issue = 4 | year = 2010 | url = https://www.who.int/medicines/publications/druginformation/innlists/PL104.pdf |  hdl=10665/74579 | hdl-access=free | page=386 }}</ref><ref>{{cite journal | vauthors=((World Health Organization)) | year=2011 | title=International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66 | journal=WHO Drug Information | volume=25 | issue=3 | page= | hdl=10665/74683 | hdl-access=free | author-link=World Health Organization }}</ref>

== References ==
{{Reflist}}

== External links ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/pacritinib | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Pacritinib }}

{{Extracellular chemotherapeutic agents}}

[[Category:Aminopyrimidines]]
[[Category:Ethers]]
[[Category:Orphan drugs]]
[[Category:Oxygen heterocycles]]
[[Category:Nitrogen heterocycles]]
[[Category:Ethanolamines]]



{{Sourceattribution|Pacritinib}}